evipedia.aidev
← Back

Empagliflozin vs. Canagliflozin for Health & Longevity

Evidence Review created on 08/30/2026 using AI4L / Grok 4.5

Also known as: Jardiance vs. Invokana, Empagliflozin versus Canagliflozin, SGLT2 Inhibitor Head-to-Head

Motivation

Empagliflozin and canagliflozin are two once-daily oral medicines that cause the kidneys to increase urinary excretion of glucose, along with some salt and water. They were developed for type 2 diabetes, then shown to protect the heart and kidneys in ways that go well beyond blood-sugar control. For adults who already invest in diet, training, and sleep, that mix of metabolic, heart, and kidney effects makes choosing between them a practical longevity question, not only a diabetes question.

Both drugs belong to the same family, but they are not interchangeable copies. One is more tightly aimed at a single kidney transporter; the other spills onto a related gut transporter at higher doses. Large manufacturer-funded outcome trials showed heart and kidney benefits for both, while a mouse longevity program tested only canagliflozin and found a male-only lifespan gain. Direct head-to-head human trials remain scarce, so most comparisons rest on separate trials, pooled analyses, and insurance-claims studies.

This review examines how empagliflozin and canagliflozin compare as tools for health and longevity: shared and unique benefits, the amputation and fracture signals, dosing and monitoring, and where the evidence is still thin.

Benefits - Risks - Protocol - Conclusion

High-level overviews that compare empagliflozin and canagliflozin, or the SGLT2 inhibitor class (kidney proteins that reclaim filtered sugar from urine), as longevity candidates.

Fewer than five high-quality overviews met the inclusion rules after excluding systematic reviews, encyclopedias, and duplicate items from the same outlet. No dedicated FoundMyFitness, Huberman Lab, Chris Kresser, or Life Extension Magazine pieces on these two drugs were found.

Grokipedia

  • Empagliflozin

    Dedicated page covering medical uses, heart-failure and kidney data, safety, pharmacology, and history for empagliflozin.

  • Canagliflozin

    Dedicated page for canagliflozin, including cardiovascular and kidney indications and the amputation discussion.

Examine

No Examine.com article for empagliflozin or canagliflozin was found. Examine.com does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article for empagliflozin or canagliflozin was found. ConsumerLab does not typically cover prescription medications.

Systematic Reviews

Network meta-analyses and class reviews that compare empagliflozin and canagliflozin on cardiorenal benefit and on principal harms.

Mechanism of Action

Empagliflozin and canagliflozin block SGLT2 in the proximal tubule (the kidney’s first reabsorption segment). Blocking it increases urinary glucose excretion by roughly 60–80 g per day, with sodium and water following. The resulting osmotic diuresis (glucose-driven water loss) lowers plasma volume, blood pressure, and cardiac preload; restored tubuloglomerular feedback (the kidney’s flow-sensing brake on filter pressure) then eases pressure inside the filtering units. An energy shortfall modestly raises ketones and may shift the heart toward ketone oxidation. A competing view holds that glucose loss is secondary and that sodium handling, uric acid, and red-cell mass drive the heart and kidney effects.

Empagliflozin is highly SGLT2-selective (about 2,500:1 versus SGLT1, the related gut and late-tubule transporter). Canagliflozin is less selective (about 160–250:1), so 300 mg also delays intestinal glucose absorption. Both are once-daily oral drugs. Empagliflozin’s plasma half-life (time for blood levels to fall by half) is about 12.4 hours; canagliflozin’s is about 10.6 hours at 100 mg and 13.1 hours at 300 mg. Both are highly protein-bound (apparent volume of distribution about 74 L for empagliflozin and 84 L for canagliflozin) and cleared mainly by UGT glucuronidation (UDP-glucuronosyltransferase enzymes that tag drugs for excretion): empagliflozin via UGT2B7, UGT1A3, UGT1A8, and UGT1A9; canagliflozin via UGT1A9 and UGT2B4. Neither is a major CYP3A4 (cytochrome P450 3A4, a liver drug-metabolizing enzyme) substrate. The kidney is the pharmacologic target; canagliflozin adds luminal SGLT1 occupancy in gut.

Historical Context & Evolution

Phlorizin, a plant glucoside, showed that blocking kidney glucose reuptake lowered blood sugar, but gut toxicity blocked clinical use. Selective SGLT2 inhibitors followed. The US Food and Drug Administration approved canagliflozin (Invokana, Janssen) in 2013 and empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) in 2014 as add-on glucose-lowering tablets.

The longevity case opened when manufacturer-funded outcome trials, required after earlier diabetes-drug safety scares, reported heart and kidney benefits far larger than the modest HbA1c (glycated hemoglobin, a three-month average blood-sugar marker) drop. EMPA-REG OUTCOME (Boehringer Ingelheim/Lilly) found less cardiovascular death and all-cause death with empagliflozin in type 2 diabetes with established atherosclerosis. CANVAS (Janssen) found less of a three-point cardiovascular composite with canagliflozin, plus more amputations. CREDENCE then showed kidney-failure reduction with canagliflozin 100 mg and no excess amputation, after which the boxed amputation warning was later removed. Empagliflozin’s EMPEROR-Reduced trial and EMPA-KIDNEY program extended heart-failure and chronic kidney disease labels, including people without diabetes. Separately, the Interventions Testing Program reported that canagliflozin extended male mouse lifespan; empagliflozin has not been tested in that protocol. Direct human head-to-head outcome trials were never run. That sequence is why longevity clinics now argue over which tablet to use, not whether the class moves cardiorenal risk.

Expected Benefits

High 🟩 🟩 🟩

Heart Failure Hospitalization Reduction

Both drugs reduce hospitalization for heart failure, a clinical event, in more than one trial. Empagliflozin cut this endpoint 35% in EMPA-REG (Boehringer Ingelheim/Lilly-funded) and cut cardiovascular death or heart-failure hospitalization 25% in EMPEROR-Reduced, including people without diabetes. Canagliflozin cut heart-failure hospitalization 33% in CANVAS (Janssen-funded). A 2024 network meta-analysis found no consistent ranking difference among SGLT2 inhibitors on this composite.

Magnitude: Heart-failure hospitalization hazard ratio (HR, relative instantaneous event rate) about 0.65–0.70 versus placebo in the major outcome trials.

Slowing of Kidney Disease Progression

Both slow hard kidney outcomes (dialysis, large sustained eGFR drop (estimated glomerular filtration rate, a blood-test estimate of kidney filtration), or kidney death). CREDENCE reduced its kidney-failure composite 30% with canagliflozin 100 mg. EMPA-KIDNEY reduced kidney progression or cardiovascular death 28% with empagliflozin 10 mg, including people without diabetes, down to eGFR near 20. Neuen’s 2019 meta-analysis found dialysis, transplant, or kidney death reduced about 33%. An early eGFR dip is hemodynamic, not injury.

Magnitude: Composite kidney-failure HR about 0.67–0.72 versus placebo; annual eGFR decline slowed by roughly 1–2 mL/min/1.73 m².

Major Adverse Cardiovascular Events Reduction

Three-point MACE (major adverse cardiovascular events: cardiovascular death, nonfatal heart attack, or nonfatal stroke) fell similarly in EMPA-REG (HR 0.86) and CANVAS (HR 0.86). CREDENCE reported HR 0.80. McGuire’s 2021 class meta-analysis pooled HR 0.90 with no significant MACE heterogeneity. Heart-attack and stroke components were largely neutral; the composite is carried by death and heart-failure pathways more than plaque rupture.

Magnitude: Three-point MACE HR 0.86 versus placebo in both EMPA-REG and CANVAS.

Atrial Fibrillation Reduction

Atrial fibrillation and flutter events fall with SGLT2 inhibition. Li’s 2020 meta-analysis of 16 trials found about a 24% relative reduction versus placebo. Zheng 2022 pooled 20 trials, including empagliflozin and canagliflozin arms, with a similar odds ratio (OR, the odds of an event on drug versus control) of 0.82. Volume and heart-failure unloading are the proposed mechanisms; a head-to-head gap between these two drugs is not established.

Magnitude: Incident atrial fibrillation or flutter relative risk about 0.76–0.82 versus placebo in randomized-trial meta-analyses.

Blood Pressure Reduction

SGLT2 inhibition lowers systolic blood pressure a few mm Hg through natriuresis (salt loss in urine) and volume contraction, without raising heart rate. The effect is seen with both drugs in EMPA-REG and CANVAS and is a validated clinical surrogate. Canagliflozin 300 mg can run slightly larger because of extra SGLT1 activity. The drop helps treated hypertension and is also a hypotensive liability with diuretics.

Magnitude: Placebo-corrected systolic blood pressure fall typically about 3–5 mm Hg; slightly larger at canagliflozin 300 mg.

Glycemic Control

Both lower HbA1c independently of insulin secretion, so hypoglycemia is uncommon unless insulin or a sulfonylurea (an insulin-releasing diabetes drug) is co-administered. Canagliflozin 300 mg often edges empagliflozin 25 mg by about 0.1–0.2 percentage points because of dual SGLT1/SGLT2 blockade, as seen in a systematic review and network meta-analysis. Glucose lowering itself does not explain the death and heart-failure effects, which appear too fast and too large. The HbA1c change is real but secondary to cardiorenal protection.

Magnitude: Placebo-corrected HbA1c reduction about 0.5–0.8% as monotherapy; canagliflozin 300 mg ~0.1–0.2% more than empagliflozin 25 mg.

Weight Loss

Urinary calorie loss plus mild volume contraction yields 2–4 kg over months, mostly fat and water, with a plateau. A systematic review and network meta-analysis found similar weight reduction at the highest doses of canagliflozin and empagliflozin. The change is replicated across trials but is far smaller than with GLP-1 receptor agonists (injectable gut-hormone medicines). For an already-lean longevity user, the metabolic shift matters more than the scale.

Magnitude: Mean loss about 2–4 kg versus placebo; highest-dose canagliflozin and empagliflozin were similar in that network meta-analysis.

Medium 🟩 🟩

Cardiovascular Death Reduction ⚠️ Conflicted

EMPA-REG reported a 38% relative reduction in cardiovascular death with empagliflozin in people with established atherosclerosis. CANVAS mixed primary and secondary prevention and did not (HR 0.87, not significant); CREDENCE was borderline (HR 0.78). McGuire’s meta-analysis found significant heterogeneity for cardiovascular death across the class. Shin’s 2025 claims study found comparable heart-attack or stroke risk for canagliflozin versus empagliflozin. Net reading: empagliflozin has the stronger dedicated death signal; a proven between-drug gap is not established.

Magnitude: Cardiovascular-death HR 0.62 in EMPA-REG versus 0.87 (nonsignificant) in CANVAS.

All-Cause Mortality Reduction ⚠️ Conflicted

EMPA-REG found 32% lower all-cause death with empagliflozin. CANVAS did not show a significant all-cause-death reduction. Silverii’s 2021 meta-analysis found a class reduction (odds ratio 0.86) with between-trial differences. Shin 2025 did not show a clear mortality gap in routine care. Net reading: a human mortality benefit is documented for empagliflozin in one large trial; treating canagliflozin as equivalent on death overreads the data.

Magnitude: All-cause-death HR 0.68 in EMPA-REG; CANVAS all-cause death not significantly reduced.

Low 🟩

Lower Uric Acid

Both increase urinary uric acid and lower serum urate. Akbari’s 2022 meta-analysis found mean drops of about 36 µmol/L for canagliflozin and 41 µmol/L for empagliflozin. Gout events are less consistently reduced than the lab value.

Magnitude: Serum urate about −34 to −41 µmol/L (−0.6 to −0.7 mg/dL) versus placebo.

Liver Fat Reduction

Both reduce liver fat on imaging in type 2 diabetes with fatty liver. Mantovani’s 2020 meta-analysis of 12 randomized trials found a 2-point drop in magnetic-resonance liver-fat percentage, with lower ALT (alanine aminotransferase, a liver enzyme). Paired biopsy data are lacking, so this remains an imaging and enzyme signal.

Magnitude: Magnetic-resonance liver-fat content about −2 percentage points versus placebo or reference therapy; no paired-biopsy figure for resolution of inflamed fatty liver.

Speculative 🟨

Male Mouse Lifespan Extension (Canagliflozin)

The Interventions Testing Program found canagliflozin extended median male mouse lifespan 14%, with no female lifespan gain. Empagliflozin has not been run in that protocol. The basis is animal lifespan, not a human trial.

Cellular Senescence Reduction

Mouse work reports that canagliflozin lowered senescent-cell markers and SASP (senescence-associated secretory phenotype, inflammatory signals from aged cells) on a high-fat diet. No controlled human senescence-outcome data exist; the basis is animal only.

Benefit-Modifying Factors

  • UGT1A9 and UGT2B4 variants: These glucuronidation enzymes clear canagliflozin; reduced-function alleles can raise exposure. Empagliflozin uses a broader UGT set, so a single-gene effect is less likely.
  • Baseline eGFR and albuminuria: Absolute kidney-event reduction is larger when filtration is already reduced or albumin (urine protein) is high; glucose lowering wanes as eGFR falls while heart-failure benefit persists.
  • Sex: Human cardiorenal relative effects look broadly similar by sex. Mouse lifespan gain is male-only; genital infections are more frequent in women.
  • Established atherosclerosis, heart failure, or chronic kidney disease: Event rates are higher, so absolute benefit is larger than in a metabolically clean adult using the drug off-label.
  • Age: Older adults still show heart-failure and kidney benefit; volume sensitivity rises, which can blunt net gain if dosing is not adjusted.
  • Starting HbA1c and body weight: Higher baseline values predict larger glycemic and weight changes; cardiorenal effects are not confined to poor glucose control.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Genital Mycotic Infections

Glycosuria (sugar in urine) feeds genital yeast. This is the most common adverse event for both drugs, replicated in EMPA-REG, CANVAS, and labels. Women and uncircumcised men are at highest risk. Infections are usually mucosal, respond to standard antifungals, and often recur if the drug continues. Shin 2025 reported slightly fewer genital infections with canagliflozin than empagliflozin in claims data.

Magnitude: Genital yeast in roughly 5–10% of women and 2–4% of men on treatment versus about 1–3% on placebo.

Volume Depletion and Hypotension

Osmotic diuresis can cause dizziness, orthostatic hypotension (a blood-pressure drop on standing), and acute creatinine rises, especially with loop diuretics, low-salt diets, or older age. Labels for both drugs warn about this, and a systematic review of SGLT2 inhibitor safety treats volume loss as a shared effect. The same volume shift likely mediates part of the heart-failure benefit. An early eGFR dip of a few mL/min is expected and usually stabilizes.

Magnitude: Volume-depletion events typically 1–3 extra percentage points versus placebo; higher when combined with diuretics.

Euglycemic Diabetic Ketoacidosis

SGLT2 inhibitors can trigger ketoacidosis (dangerous blood-acid buildup from ketones) even when glucose is not very high, especially with insulin reduction, fasting, illness, surgery, alcohol, or a ketogenic diet. Both labels warn. Yang’s 2023 network meta-analysis found increased DKA (diabetic ketoacidosis) risk across the class. Incidence in type 2 diabetes trials is low; in type 1 diabetes it is unacceptably high, which is why neither drug is used there.

Magnitude: Trial incidence typically well under 1 per 100 patient-years in type 2 diabetes; substantially higher if insulin is withdrawn or carbohydrate intake is very low.

LDL Cholesterol Increase

Both drugs raise LDL (low-density lipoprotein, the main atherogenic blood cholesterol particle) a few mg/dL, likely from hemoconcentration and metabolic shift, as recorded in EMPA-REG and CANVAS. The change is small next to the event reductions but is the wrong direction for an apoB (apolipoprotein B, the particle count of atherogenic lipoproteins) protocol, which is why lipids are rechecked after start.

Magnitude: LDL-C typically rises about 3–8 mg/dL versus placebo.

Medium 🟥 🟥

Lower-Limb Amputation ⚠️ Conflicted

CANVAS found almost a doubling of mainly toe and metatarsal amputations with canagliflozin (HR 1.97). CREDENCE at 100 mg and empagliflozin outcome trials did not. See’s 2022 amputation meta-analysis is driven largely by CANVAS; FDA later removed a boxed warning. Net reading: the CANVAS signal is real in that dataset but is not a proven class effect, so canagliflozin still carries extra residual uncertainty versus empagliflozin.

Magnitude: CANVAS amputation HR 1.97 (6.3 vs 3.4 per 1,000 patient-years); CREDENCE and empagliflozin trials without a significant excess.

Bone Fracture ⚠️ Conflicted

CANVAS reported more fractures with canagliflozin; pooled non-CANVAS studies (Watts 2016) and CREDENCE did not. Zhou 2019 could not fully explain the CANVAS-versus-CANVAS-R split; falls from volume depletion remain a candidate mechanism. Empagliflozin trials have not shown a fracture excess. Net reading: a canagliflozin-specific fracture liability is possible but not consistent across its own trials; empagliflozin looks cleaner on bone.

Magnitude: CANVAS fracture HR about 1.55 in that trial; CREDENCE and empagliflozin programs without a significant increase.

Low 🟥

Fournier Gangrene

Post-marketing cases of necrotizing perineal infection (Fournier gangrene, a rapidly spreading genital/perineal bacterial infection) have been reported with SGLT2 inhibitors, including both drugs. Bersoff-Matcha’s 2019 FDA case series established the association. Events are rare, severe, and surgical. Glycosuria plus a mucosal break is the proposed setup.

Magnitude: Very rare in trials; dozens of post-marketing cases across the class rather than a stable incidence rate.

Urinary Tract Infection

Labels list UTI (urinary tract infection). Trial excess versus placebo is inconsistent and smaller than the genital-yeast signal in a systematic review of SGLT2 inhibitor safety. Shin 2025 found more severe UTIs with canagliflozin than empagliflozin. Complicated kidney infections remain uncommon.

Magnitude: Empagliflozin label UTI about 7.6% at 10 mg; between-drug excess is small and not consistent across randomized trials.

Speculative 🟨

Female Late-Life Harm (Canagliflozin, Mice)

Late-life canagliflozin start reduced female mouse lifespan in a follow-on Interventions Testing Program cohort, with higher drug levels in aged females. No equivalent human signal is established; the basis is animal work only.

Risk-Modifying Factors

  • UGT1A9 reduced-function alleles: Higher canagliflozin levels may increase volume-related and genital adverse events; empagliflozin is less dependent on this single enzyme.
  • Low baseline eGFR, high hematocrit, or low blood pressure: Amplify volume depletion, the early creatinine bump, and dizziness.
  • Sex: Genital yeast is more common in women; uncircumcised men get mycotic balanitis (a yeast infection of the glans). Mouse late-life harm is female-specific.
  • Peripheral artery disease (PAD, narrowed leg arteries), prior amputation, neuropathy, or active foot ulcer: The groups in which the CANVAS amputation signal concentrated; extra caution for canagliflozin.
  • Age ≥65, diuretic use, or low-salt intake: Raise dehydration and fall risk, which may also mediate fractures.

Key Interactions & Contraindications

  • Insulin and sulfonylureas (glipizide, glyburide): Caution — added hypoglycemia risk. Mitigate by reducing the insulin or sulfonylurea dose when starting.
  • Loop and thiazide diuretics (water pills such as furosemide, hydrochlorothiazide): Caution — stacked volume loss, dizziness, and creatinine rise. Mitigate by holding or cutting the diuretic around initiation.
  • ACE inhibitors (angiotensin-converting enzyme blockers such as lisinopril) / ARBs (angiotensin receptor blockers such as losartan) and mineralocorticoid blockers (salt-and-potassium hormone blockers such as spironolactone, finerenone): Monitor — expected eGFR dip and potassium shifts; the finerenone combination is used on purpose in kidney disease.
  • Lithium: Monitor — increased lithium clearance from natriuresis can lower lithium levels.
  • Digoxin with canagliflozin: Caution — canagliflozin can raise digoxin exposure via P-glycoprotein (a gut/kidney drug pump); empagliflozin has less of this effect.
  • Rifampin and other UGT inducers: Caution — they lower canagliflozin levels more than empagliflozin levels.
  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen, naproxen): Caution — stacked kidney-perfusion stress during volume depletion. Hold during illness.
  • Oral ketogenic supplements, exogenous ketones, and very-low-carbohydrate diets: Caution — additive ketoacidosis risk. Separate from fasting and peri-procedure starvation.
  • GLP-1 receptor agonists (semaglutide, tirzepatide): Caution — additive weight, glucose, and kidney-albumin effects; watch volume and eating during titration.
  • Blood-pressure supplements (beetroot, high-dose magnesium, potassium salts): Monitor — additive hypotensive or potassium load with the natriuretic effect.

Populations who should avoid Empagliflozin vs. Canagliflozin:

  • Type 1 diabetes (ketoacidosis risk is too high for both).
  • Known serious hypersensitivity to empagliflozin or canagliflozin.
  • Dialysis or an eGFR below the labeled threshold for the intended use (empagliflozin kidney use down to ~20; canagliflozin kidney use studied from 30).
  • Pregnancy and breastfeeding.
  • Active Fournier gangrene, severe genital infection, or an untreated foot ulcer (especially canagliflozin if prior amputation).

Risk Mitigation Strategies

  • Morning dosing plus extra fluid on hot or training days: Offsets osmotic diuresis and reduces dizziness and the early creatinine bump.
  • Hold 3–4 days before major surgery or prolonged fasting: Lowers euglycemic ketoacidosis risk around not-eating periods.
  • Sick-day ketone checks: Fingerstick or urine ketones during vomiting, infection, or very-low-carb eating prevent missed ketoacidosis.
  • Foot inspection if PAD or neuropathy is present: Daily skin checks and prompt ulcer care address the CANVAS amputation pattern, especially on canagliflozin.
  • Diuretic down-titration at start: Cutting the loop diuretic for 1–2 weeks limits hypotension while preserving heart-failure benefit.
  • Genital hygiene and early antifungal treatment: Reduces recurrent yeast from glycosuria without automatic drug stop.
  • Canagliflozin avoided after amputation or hip fracture in many clinics: That practice sidesteps CANVAS residual uncertainty when those risks already dominate.

Therapeutic Protocol

  • Conventional cardiorenal protocol: Empagliflozin 10 mg once daily, or canagliflozin 100 mg once daily, continued indefinitely for heart failure or chronic kidney disease.
  • Glycemic up-titration: Empagliflozin 25 mg if 10 mg is tolerated; canagliflozin 300 mg if eGFR ≥60 and extra glucose lowering is the aim.
  • Longevity off-label use: Some longevity clinicians (Attia’s discussions of the class) favor empagliflozin 10 mg for the human death dataset; others favor canagliflozin because only it has Interventions Testing Program lifespan data.
  • Time of day: Empagliflozin morning, with or without food. Canagliflozin before the first meal, per label, because of its SGLT1 gut effect.
  • Half-life and splitting: Half-lives of ~11–13 hours support once-daily dosing; split doses are not used.
  • UGT1A9 consideration: Reduced-function variants may warrant staying at canagliflozin 100 mg rather than 300 mg; empagliflozin 10 mg is the simpler default.
  • Sex: No routine dose split by sex in humans; women need yeast counseling, and mouse data do not support a female longevity claim for canagliflozin.
  • Older adults: Start at the 10 mg / 100 mg floor, recheck volume and eGFR at 2–4 weeks, and avoid stacking new diuretics.
  • Baseline eGFR: Empagliflozin 10 mg remains the heart/kidney dose down to eGFR ~20; canagliflozin 100 mg was the CREDENCE dose from eGFR 30.
  • Heart failure or albuminuric kidney disease: These conditions, not HbA1c, are what actually change the benefit-risk math for long-term use.

Discontinuation & Cycling

  • Duration: Cardiorenal protection is treated as long-term, not a course of therapy; glucose-lowering can be stopped if another agent takes over.
  • Withdrawal: No classic rebound syndrome. Volume and eGFR drift back toward baseline over days to weeks after stopping.
  • Taper: A pharmacologic taper is not required; holding around surgery is a pause, not a wean.
  • Cycling: Cycling is not used to preserve efficacy. Benefit tracks ongoing SGLT2 blockade, and restarting reintroduces yeast and volume effects.
  • Peri-procedure hold: Typical practice is to stop 3–4 days before major surgery or a prolonged fast, then restart when eating and volume are stable.

Sourcing and Quality

  • Prescription status: Both are FDA-approved oral tablets (Jardiance; Invokana), not dietary supplements. Research-chemical powders are a purity and dosing hazard.
  • Brand and combination products: Empagliflozin is co-formulated with metformin or linagliptin; canagliflozin with metformin. Matching the intended dose of the SGLT2 component matters more than the brand name.
  • Generics: FDA has approved canagliflozin generics, but US pharmacy supply remains limited by remaining patents; empagliflozin is still brand-priced in most US channels.
  • What to verify: Pharmacy-dispensed, intact unit-dose tablets; avoid compounded “longevity blends” that do not match labeled 10/25 mg or 100/300 mg strengths.
  • Manufacturer identity: Boehringer Ingelheim/Lilly (empagliflozin) and Janssen/J&J (canagliflozin) ran the outcome trials; that commercial stake is why independent claims studies such as Shin 2025 matter.

Practical Considerations

  • Time to effect: Glycosuria and a small weight/blood-pressure change appear within days. Heart-failure benefit separates within weeks to months. Kidney-slope benefit is judged over 6–12 months.
  • Common pitfalls: Starting on a ketogenic fast; stacking a new diuretic; ignoring genital symptoms; reading the early eGFR dip as injury; assuming canagliflozin 300 mg is “more longevity” rather than more SGLT1.
  • Regulatory status: On-label for type 2 diabetes, and — with different exact sentences — for heart failure and kidney disease. Use in a non-diabetic adult without those diagnoses is off-label.
  • Cost: US cash prices commonly run several hundred dollars per month for brand tablets. Formulary contracts give payers a systematic incentive to prefer one tablet, a structural bias in coverage policy, guideline formation, and research funding.

Interaction with Foundational Habits

  • Sleep: Direct, potentially disrupting. Osmotic diuresis raises nocturnal urination for the first weeks; morning dosing and afternoon fluid front-loading usually blunt that.
  • Nutrition: Potentiating and hazardous depending on the diet. Carbohydrate intake scales glycosuria; a ketogenic or prolonged-fasting pattern plus either drug raises ketoacidosis risk and needs ketone monitoring.
  • Exercise: Indirect, mostly volume. Heat, long endurance sessions, and sauna stack with diuresis; extra fluid and a rest-day hold during illness prevent dizziness. No consistent hypertrophy-blunting signal.
  • Stress management: Indirect. Natriuresis and a small blood-pressure drop can help a high-output stress phenotype but will worsen orthostasis in a volume-depleted one.

Monitoring Protocol & Defining Success

Before the first dose, labs establish kidney filtration, electrolytes, glucose burden, and hematocrit, because these drugs concentrate blood slightly and cause an early filtration dip that must be told from injury. Blood pressure, weight, and a foot exam belong in that same visit, especially if canagliflozin is the candidate. Recheck at 2–4 weeks confirms creatinine has stabilized and that dizziness or yeast are manageable. At about 12 weeks, HbA1c, lipids, and weight are captured.

Ongoing cadence is 2–4 weeks, 12 weeks, then every 3–6 months, or sooner after diuretic changes or illness. Success is a slower filtration slope, modest weight and pressure decline without orthostasis, and no recurrent yeast or ketone crises — not a dramatic HbA1c collapse.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
eGFR (creatinine) Track personal slope; many functional clinics aim ≥90 mL/min/1.73 m² Detects the early dip versus true decline Conventional “normal” is ≥60; fast 8–12 h; recheck 2–4 weeks after start
Serum creatinine Change from the person’s own baseline; no single functional target Pairs with eGFR to flag injury versus hemodynamics Rise of ~0.2–0.3 mg/dL early can be expected; larger or progressive rises are not
Sodium, potassium Na 138–142 mmol/L; K 4.0–4.9 mmol/L (functional); conventional Na 135–145, K 3.5–5.0 Volume and potassium shifts with natriuresis Recheck sooner if on ACE inhibitor/ARB, finerenone, or diuretic
HbA1c Functional often <5.4–5.6%; diabetes conventional target <7% Confirms glucose effect and hypoglycemia risk with insulin Not the main success metric for cardiorenal use
Hematocrit / hemoglobin Track rise from baseline; hematocrit often 40–50% in men, 36–46% in women SGLT2 inhibitors raise red-cell mass via hemoconcentration and erythropoietin Large jumps plus headache or visual change need a second look
UACR Functional <10–30 mg/g; conventional <30 mg/g Early kidney-response marker UACR is urine albumin-to-creatinine ratio; morning sample; pair with eGFR
LDL-C / apoB apoB (atherogenic particle count) often <60–80 mg/dL in aggressive protocols Captures the small LDL rise Recheck at 12 weeks; conventional LDL-C <100 mg/dL is looser than functional apoB targets
Blood pressure Systolic often 110–120 mm Hg if tolerated Tracks benefit and hypotensive overshoot Standing BP if dizzy
Body weight Change from baseline (typical −2 to −4 kg) Confirms caloric/volume effect and over-diuresis Daily home weights during the first month
Blood or urine ketones Not a numeric “optimal”; treat rising ketones plus symptoms as a stop signal Catches euglycemic ketoacidosis early Check during illness, fasting, or ketogenic eating

Qualitative markers:

  • Night-time urination frequency and sleep continuity
  • Thirst, standing dizziness, exercise heat tolerance
  • Genital itching, discharge, or redness
  • Foot skin integrity, new pain, or slow-healing sores
  • Energy, training load, and unexplained nausea or breathing discomfort (ketone warning)

Emerging Research

  • Pragmatic empagliflozin versus dapagliflozin trial: NCT06642272 is recruiting ~17,200 people into an electronic-health-record cluster comparison of two SGLT2 inhibitors on heart and kidney outcomes — a real head-to-head, though canagliflozin is not an arm.
  • Aldosterone-synthase plus empagliflozin: EASi-KIDNEY (NCT06531824, ~11,000) and a heart-failure companion (NCT06424288, ~6,000) test vicadrostat with empagliflozin. Positive results would strengthen empagliflozin’s combination evidence, not canagliflozin’s.
  • Post-heart-attack caution: EMPACT-MI (NCT04509674) did not clearly reduce death or first heart-failure hospitalization with early empagliflozin after myocardial infarction, a reminder that the class is not a universal cardiac shield.
  • Mouse longevity, sex, and drug levels: Late-start canagliflozin still lengthened male mouse life and shortened female life in follow-on Interventions Testing Program pathology work (Snyder et al., 2026). That could weaken a female longevity case for canagliflozin.
  • Claims-based head-to-head: Shin et al., 2025 found broadly comparable cardiovascular effectiveness at full doses, which would weaken marketing claims that one tablet uniquely prevents heart attack or stroke.

Conclusion

Empagliflozin and canagliflozin are sibling kidney-sugar medicines that share modest blood-sugar lowering, a few kilograms of weight loss, a small drop in blood pressure, fewer heart-failure hospitalizations, and slower kidney decline. Those effects show up in diabetes, heart failure, and chronic kidney disease, and they are large enough to matter to a health-optimizing adult who already treats metabolic load as a longevity problem.

They are not the same drug. Empagliflozin has the cleaner human death signal in its first large heart trial and more approved heart-failure and kidney uses. Canagliflozin has the only gold-standard mouse lifespan dataset in the pair, and it is more likely to inhibit a second gut transporter at the high dose. The price of that extra activity, and of canagliflozin’s trial history, is a still-unsettled amputation and fracture story that did not appear in empagliflozin’s major trials and did not repeat in canagliflozin’s kidney trial. Direct human head-to-head outcome trials are almost absent; claims of superiority rest on separate trials, pooled analyses, and insurance data, much of it paid for by Boehringer Ingelheim/Lilly and Janssen. Insurer coverage lists also systematically favor the cheaper tablet.

Genital yeast infections and volume loss are the everyday trade-offs for both. Rare acid-buildup crises and a very rare rapidly spreading genital infection sit in the tail. For a proactive adult, the comparison is less whether the class moves heart and kidney risk — it does — than which risk texture and which evidence base one is willing to live with.

Top - Benefits - Risks - Protocol